C88.0
Waldenström macroglobulinemia
Clinical Classification Guidelines
Inclusion Terms
- Lymphoplasmacytic lymphoma with IgM-production
- Macroglobulinemia (idiopathic) (primary)
Excludes Type 1
- small cell B-cell lymphoma (C83.0)
Medical Intelligence & Overview
Waldenström macroglobulinemia is a rare type of blood cancer characterized by the overproduction of abnormal B lymphocytes that produce large amounts of a specific protein called IgM. This disease falls under the category of lymphoplasmacytic lymphoma, a cancer that involves a dense accumulation of lymphoplasmacytic cells in the bone marrow, blood, and sometimes lymph nodes. The increased levels of IgM can cause a range of health issues, including blood thickening and immune system problems. Recognized by the ICD-10 code C88.0, this condition primarily affects older adults and requires careful medical management.
Causes & Symptoms
Clinical Causes: The exact cause of Waldenström macroglobulinemia remains unknown. Researchers believe it results from a combination of genetic and environmental factors. Some potential contributing elements include: - Genetic mutations or abnormalities in DNA - Family history of blood cancers - Exposure to certain chemicals or environmental toxins - Age-related changes in immune function While the precise triggers are not well understood, ongoing research aims to identify specific risk factors that may increase susceptibility to this disease.
Key Symptoms: The symptoms of Waldenström macroglobulinemia can vary widely and often develop gradually. Common signs and symptoms include: - Fatigue and weakness - Weight loss - Fever and night sweats - Swollen lymph nodes - Bleeding or easy bruising - Vision problems or headaches due to thickened blood - Shortness of breath - Persistent infections - Numbness or tingling in the extremities Some individuals might experience no symptoms initially and discover the condition during routine blood tests. Over time, the accumulation of abnormal cells and elevated IgM levels can lead to complications affecting various organs.
Diagnostic & Treatment
Diagnosis Path: Diagnosing Waldenström macroglobulinemia involves several steps to confirm the presence of abnormal cells and elevated IgM levels: - Blood tests: Measure levels of IgM and other blood components - Serum protein electrophoresis: Detects abnormal proteins - Bone marrow biopsy: Examines marrow tissue for abnormal lymphoplasmacytic cells - Imaging studies (CT scans): Assess lymph nodes and organ involvement - Additional tests: Include flow cytometry and genetic analyses to identify specific cell markers and mutations A combination of these assessments helps physicians establish an accurate diagnosis and determine disease stage.
Treatment Protocols: While some patients with mild symptoms may be monitored without immediate treatment, others require intervention to manage symptoms and prevent complications. Common treatment approaches include: - Chemotherapy: To reduce abnormal cell proliferation - Targeted therapies: Such as proteasome inhibitors and monoclonal antibodies - Plasmapheresis: A procedure that filters excessive IgM from the blood, used especially when blood thickening poses a risk - Immunotherapy: Enhances immune response to attack cancer cells - Supportive care: Including blood transfusions, antibiotics for infections, and medications to address specific symptoms Treatment plans are tailored based on disease severity, patient health, and response to therapy. Regular monitoring remains essential to adapt treatment as needed.
Clinical Advice & FAQs
Billing Guidance
Is C88.0 a billable ICD-10 code?
Yes, C88.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C88.0?
Clinical documentation must specify the nature of Waldenström macroglobulinemia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference